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The receptor tyrosine kinase family of ﬁbroblast growth factor receptors (FGFRs) play
crucial roles in embryonic development, metabolism, tissue homeostasis and wound
repair via stimulation of intracellular signalling cascades. As a consequence of FGFRs’
inﬂuence on cell growth, proliferation and differentiation, FGFR signalling is frequently
dysregulated in a host of human cancers, variously by means of overexpression, somatic
point mutations and gene fusion events. Dysregulation of FGFRs is also the underlying
cause of many developmental dysplasias such as hypochondroplasia and achondropla-
sia. Accordingly, FGFRs are attractive pharmaceutical targets, and multiple clinical trials
are in progress for the treatment of various FGFR aberrations. To effectively target dysre-
gulated receptors, a structural and mechanistic understanding of FGFR activation and
regulation is required. Here, we review some of the key research ﬁndings from the last
couple of decades and summarise the strategies being explored for therapeutic
intervention.
Introduction
Through their role in signal transduction pathways, protein kinases mediate a plethora of cellular
phenotypic changes such as cell growth, proliferation, differentiation and survival [1]. Receptor tyro-
sine kinases (RTKs) are an important kinase subfamily whose members span the cell surface and acti-
vate intracellular signalling cascades in response to exogenous growth signals via binding of
family-speciﬁc extracellular ligands. Canonically, this is achieved through ligand-driven receptor
dimerisation and subsequent trans-autophosphorylation of the cytosolic receptor tyrosine kinase
domains, stimulating kinase activity [2]. Alternatively, in cases where receptors are believed to exist as
constitutive dimers, activation can be achieved allosterically via ligand-induced conformational rear-
rangements of the receptors. Fibroblast growth factor receptors (FGFRs), the focus of this review, are
one of these RTK subfamilies, responding to the binding of ﬁbroblast growth factors (FGFs)
(Figure 1) [2,3]. Through their activation, FGFRs have roles in embryonic development, tissue homeo-
stasis and metabolism [4–7].
The FGFR family is composed of four separately encoded yet highly homologous receptors, FGFRs
1–4, sharing between 56 and 71% sequence identity [8]. Structurally, all members share the same
architecture consisting of a large ligand-binding extracellular domain (ECD) that comprises three
immunoglobulin (Ig)-like domains (D1–3); a single membrane-spanning helix; and an intracellular
domain containing the catalytically active ‘split’ tyrosine kinase domain (Figure 1). Genetic, biochem-
ical and structural studies have yielded extensive insights into understanding of FGFR activation.
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Localisation of FGF ligand binding and receptor
dimerisation
In mammals, there are 18 FGF ligands which can be subdivided into paracrine and endocrine families; all
FGFs have a beta-trefoil fold with a heparan sulfate binding-site on its surface that facilitates sequestration of
FGF ligands close to the cell surface for receptor binding [9,10]. FGF-ligand binding to FGFRs is localised to
domains D2 and D3 of the extracellular domain [11], and in the case of paracrine FGFs, occurs in association
with heparan sulfate proteoglycan cofactors [10] (Figure 1). While FGFs are able to bind independently to
FGFRs in a 1:1 stoichiometry [12–14], heparan sulfate (or heparin) is necessary for receptor dimerisation and
FGFR signalling [15–17]. Although dimerisation of a variety of 1:1 FGF:FGFR extracellular domain complexes
was initially observed crystallographically in the absence of heparin [13,14,18], this dimerisation is likely to be a
crystallisation artefact. However, these heparin-free crystallographically dimerised complexes were nonetheless
useful for building models of heparin-mediated receptor dimerisation and are structurally similar to a 2:2:2
stoichiometry FGF2:FGFR1:heparin ternary complex structure solved at a later date (Figure 2) [19]. The stoichi-
ometry and minimal heparan sulfate chain length required for receptor dimerisation have been disputed,
resulting in different proposed models of FGFR activation [19–23]. However, regardless of the model, in all
FGF:FGFR complex structures, FGF ligands make contacts with residues from D2, the D2–D3 linker and D3
domains of FGFRs, with the interfaces characterised by both hydrophobic and polar interactions. In the 2:2:2
stoichiometry ternary complex model, both FGF ligands and heparin make contacts with both FGFR molecules
of the dimer (Figure 2). Unlike paracrine FGFs, endocrine FGFs such as FGF21 and FGF23 exhibit lower
binding afﬁnity for heparan sulfate [10] and require Klotho co-receptors to act as cofactors for activation of
FGFRs [7,24,25].
Though structurally homologous, FGFR family members exhibit different binding speciﬁcities to subsets of
the 18 FGF ligands [8,10]. While some FGFs, namely FGF1 (acidic FGF) and FGF2 (basic FGF), show binding
redundancy among the FGF receptors, others bind to sole members or only some of the family [8]. This
variety in ligand-binding speciﬁcity is enhanced by tissue-speciﬁc alternative splicing of the third Ig-like
domain D3 of FGFRs 1–3 [10,11,26,27] and can be attributed, in part, to consequent changes in FGF–FGFR
contacts at the βC0-βE region of D3 [13].
The extracellular domain also displays receptor autoinhibition mechanisms, realised by the blocking of FGF
binding by domain D1 and the D1–D2 ‘acid-box’ linker [23]; studies of alternative splicing of this region and
biophysical analyses suggest that autoinhibition is mediated by competition between ‘acid box’ and heparan
sulfate binding, and through back-binding of D1 to the FGF binding-site on domains D2 and D3 [28–31].
Figure 1. Stimulation of FGFRs.
FGFRs are composed of an extracellular domain comprising D1, acid box, and D2 and D3 domains, followed by a single helix
TMD, the JMD, and an intracellular ‘split’ tyrosine KD. Two models describing receptor stimulation by FGF ligand and heparin/
heparan sulfate cofactor have been described: the canonical ligand-induced receptor dimerisation model (left) and an allosteric
ligand-induced conformational change model (right). Receptor activation leads to trans-autophosphorylation of the kinase
domains and stimulation of intracellular signalling cascades. The boxed regions (A–C) correspond to those in Figure 2.
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Dimerisation of FGFRs at the transmembrane domain and
an alternative stimulation model
The dimerisation of the extracellular domains of FGFRs presumably positions the C-terminal ends of D3
domains such that the intracellular tyrosine kinase domains are arranged to perform trans-
autophosphorylation; this would require the passing of spatial and conformational information across the
plasma membrane. Studies of FGFR transmembrane domains (TMDs) are sparse; however, nuclear magnetic
A
B
C
Figure 2. Structures of FGFR extracellular, transmembrane, and kinase domains.
(A) Crystal structure of FGFR1 extracellular domains D2 and D3 (grey cartoon on transparent surface representation) in a
2:2:2 complex with FGF2 (light green, cartoon) and heparin (dark blue, sticks) (PDB: 1FQ9). Only one copy of FGF2 and FGFR1
are shown in cartoon representation for clarity. (B) An FGFR3 transmembrane domain dimer derived from NMR (PDB: 2LZL) in
cartoon representation with the observed dimerisation interface and GxxxG-like motifs highlighted. (C) FGFR3 kinase domain
crystal structure (PDB: 4K33) in cartoon representation on a transparent surface with the N- and C-lobes and structural
elements, the αC helix (salmon), the P-loop (orange), the catalytic loop (blue), the A-loop (yellow), the kinase hinge (magenta)
and the (incomplete) kinase insert (black) highlighted. Panels are not in scale with one another.
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resonance studies of FGFR3 transmembrane domain in d38-dodecylphosphocholine/d29-sodium dodecyl sulfate
(9/1) micelles revealed a symmetric left-handed dimer of helices with 310 and alpha-helical character (Figure 2)
[32]. In this structure, the two helices cross one another with an angle of 23°, approximately at the midpoint of
the helix length. However, this crossing does not occur at the GxxxG-like motifs of the helices which are
observed at dimerisation interfaces of other receptor tyrosine kinases [33–35] and lie immediately upstream of
the NMR-observed cross-point. The canonical model of receptor tyrosine kinase activation proceeds via
ligand-induced dimerisation, but recent evidence suggests that FGFRs 1–3 may possess intrinsic dimerisation
potential even when unliganded [36,37]. Consequently, an allosteric activation model featuring ligand-induced
conformational change could be more appropriate for FGFRs (Figure 1), similar to that of insulin receptor tyro-
sine kinase [38]. Under this model, it is expected that there will be more than one dimerisation state of the
transmembrane domain, reﬂecting different ligand binding at the extracellular domains. The extent of conform-
ational change induced by ligand binding, perhaps manifested as the degree of C-terminal helix separation,
could correlate to the level of kinase activation and signalling outcome. Altogether, these suggest that the
NMR-observed symmetrical dimer may correspond to the basal dimerisation state of the receptor, while the
alternative dimer interface at the GxxxG-like motifs may be that of the fully active state [32]. Additional inter-
mediate activation states with alternative dimerisation interfaces cannot be ruled out. Further independent data
lend support to the allosteric model: crystal structures of the extracellular region of FGFR2c bound to FGF8b
and FGF2 show variation in the distances between D3 domain C-termini of ∼35 Å and ∼46 Å, respectively
[10]. Furthermore, Förster resonance energy transfer (FRET)-based studies of FGF1 and FGF2 binding to
FGFRs 1–3 show differences in ligand-induced helix separation, and at least in the case of FGFR3, this further
correlates with the level of receptor (auto)phosphorylation [27,36].
The heart of the action: the FGFR tyrosine kinase domain
The intracellular ‘split’ tyrosine kinase domain of FGFRs shares the prototypical bi-lobed kinase fold (Figure 2)
[39–42]. Binding of both adenosine triphosphate (ATP) and substrate occurs at the cleft between the two lobes.
Nucleotide binding is facilitated by interactions with N-lobe residues of the hinge region, the glycine-rich
P-loop (or nucleotide binding loop) which folds over and encloses ATP for phosphotransfer, and of conserved
residue K514 (FGFR1) of helix αC (stabilised by salt-bridge formation with equally conserved E531 (FGFR1)).
On the other hand, substrate binding is orchestrated by the C-lobe. Phosphorylation is catalysed by an invariant
aspartate residue (D623 in FGFR1) of the His-Arg-Asp (HRD) motif, conserved among protein kinases and
located on the C-lobe in the αE-β7 (catalytic) loop. Thus, to attain a catalytically competent state, the N- and
C-lobes of the kinase require rotation towards one another during transition from the inactive state. During
receptor activation, the kinase domains autophosphorylate one another in the dimer, ﬁrstly at Y653 (FGFR1) of
the YYKK motif in the activation loop (A-loop) [43]. Seven phosphorylatable tyrosine residues have been iden-
tiﬁed in FGFR1 (Y463, Y583, Y585, Y653, Y654, Y730 and Y766), ﬁve of which are phosphorylated in an
ordered fashion in vitro [43–46]. Tyrosine residues Y653 and Y654 are essential for kinase activity and their
phosphorylation increases catalytic activity 50–100 and 500–1000 fold, respectively [43]. Other phospho-Tyr
residues serve as docking sites for SH2 domain-containing adaptor proteins for the stimulation of downstream
signalling cascades (Figure 1); for example, phospho-Y766 of FGFR1 serves as a binding-site for phospholipase
Cγ (PLCγ) [47,48]. Likewise, Y724 of FGFR3 (equivalent to Y730 of FGFR1) appears to play a central role in
FGFR3-mediated signalling, affecting activation of phosphoinositide 3-kinase (PI3K), signal transducer and
activator of transcription protein (STAT) and mitogen-activated protein kinase (MAPK) pathways [49,50].
Immediately upstream of the kinase domain, the juxtamembrane domain ( JMD) serves as a further site for
coupling of receptor activation to downstream signalling cascades; here, the phosphotyrosine-binding domain
of FGFR substrate 2 (FRS2α) binds constitutively to FGFR1 in a non-canonical, phosphotyrosine-independent
manner and upon its own FGFR-dependent phosphorylation acts as a scaffold for Grb2 adaptor protein for
MAPK signalling [51–53].
Activity regulation of the kinase domain
To trans-autophosphorylate in response to ligand binding, the FGFR kinase domain requires an intrinsic basal
kinase activity. This requirement has led to a ‘two-state’ dynamic equilibrium model of kinase activation
wherein a kinase can exhibit ensembles of a rigid, catalytically ‘inhibited’ state, or a dynamic, conformationally
heterogeneous active state [54,55]. Under this model, kinase activity can be ﬁne-tuned by shifting the kinase
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population between these two states. It is essential that kinases are tightly regulated, ensuring the ability for
trans-autophosphorylation while preventing overstimulation of signalling cascades; dysregulation of FGFR
kinases underpins a plethora of pathologies including developmental abnormalities such as achondroplasia,
hypochondroplasia and lacrimo-auriculo-dento-digital (LADD) syndrome, and a host of human cancers
[3,56,57].
In the basal, unstimulated state, the kinase domain is autoinhibited and has minimal kinase activity.
Mechanisms of autoinhibition vary between kinases [2], and in FGFRs is achieved by the steric blocking of sub-
strate Tyr binding by the protein tyrosine kinase-invariant P663 (FGFR1) at the C-terminal end of the A-loop
[39]. Additionally, the so-called molecular brake of FGFR kinases, located at the kinase hinge, has a critical role
in establishing autoinhibition and, via its release, activation (Figure 3) [40]. This structural motif is composed
of a hydrogen bonding network between FGFR2 residues H544 and N549 (of the αC–β4 loop), E565 (of the
kinase hinge) and K641 (of β8) in autoinhibited kinases (H541, N546, E562 and K638, respectively, in FGFR1),
but is found to dissociate in activated kinase domain crystal structures (Figure 3) [40]. The release of the
molecular brake occurs concomitantly with local A-loop conformational changes from an autoinhibited,
substrate-blocked to an extended conformation, and the global conformational rotation of the αC helix (and
N-lobe) towards the C-lobe, facilitating the generation of a catalytically competent state. The extended active
A-loop conformation of the kinase is stabilised by salt-bridge interactions between phospho-Y657 (of FGFR2,
equivalent to Y654 of FGFR1) and conserved residue R649 (of FGFR2), also of the A-loop (Figure 3) [40].
Residues of the molecular brake region are mutated in patients with dwarﬁsm and glioblastoma, highlighting
its importance in kinase activity regulation [40,58].
A
B
Figure 3. Comparison of active and inactive FGFR kinase domain states.
(A) Structural overlay (right) of non-phosphorylated, inactive FGFR2 kinase domain (light grey) (PDB: 2PSQ) and
phosphorylated, active FGFR2 kinase domain (blue) (PDB: 2PVF), both in cartoon representation. Additionally, in the active
kinase domain, the kinase regulatory spine and two participating residues, H624 of the HRD motif and F645 of the DFG motif,
are highlighted in red sticks and surface representation. During kinase activation, the molecular brake hydrogen bonding
network between H544, N549, E565, and K641 of FGFR2 is broken, as illustrated in the expanded sections (left). The same
regions in the inactive state of FGFR1 kinase (PDB: 4V01) (dark grey) with the corresponding H541, N546, E562, and K638
residues are also presented (far left), illustrating the conservation of this feature among FGFRs. (B) Structural differences in
A-loop conformation in active and inactive FGFR2 kinase domains where phosphorylation-dependent salt bridge interactions
between R649 and phospho-Y657 (pY657) stabilise an extended conformation of the loop in the activated kinase.
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Additional structural features of the kinase domain, including Asp-Phe-Gly (DFG)-motif conformation and
kinase hydrophobic spines, are indicators of kinase activity status [59,60]. The DFG-motif, located at the start
of the A-loop, classically exists in one of two states: the catalytically competent DFG-in and catalytically incom-
petent DFG-out state [61–63]. When in the DFG-in state, the Asp residue of the DFG-motif plays an essential
role in ATP binding through coordination of all three phosphate groups of ATP, either directly or via magne-
sium ions; these interactions are not possible in the DFG-out state [62]. Furthermore, the ‘ﬂipping’ of the DFG
motif by ∼180° to its DFG-out position breaks the hydrophobic regulatory spine of the kinase. The regulatory
spine is a structural entity that spans the N- and C-lobes of a kinase, composed of H624 (FGFR2) of the HRD
motif, F645 (FGFR2) of the DFG motif and aliphatic side-chains of residues located on N-lobe elements αC
and β4 (Figure 3). Conserved across kinases, its assembly is a hallmark of the active kinase state. A second
hydrophobic spine, the catalytic spine, is assembled upon ATP binding, where the adenine base bridges further
hydrophobic entities in the N- and C-lobes [59,64]. Recent analysis of inhibited, partially activated and fully
activated (phosphorylated) FGFR kinase domains has revealed an interconnected allosteric network at the N-
and C-lobe interface, permitting long-distance communication between the molecular brake and A-loop [65].
This allosteric network comprises the molecular brake, an ‘A-loop plug’ element (which holds the loop in a
substrate-binding incompatible conformation), and hydrophobic patches of residues termed the DFG-latch and
αC-tether. While these are distinct from those elements discussed previously, they are intimately associated
with DFG-motif and αC conformational states. Strikingly, naturally found mutations within these elements
alter the activity level of the kinase in vitro, with combined double mutations in different elements demonstrat-
ing additive effects, reﬂecting a population shift in the two-state dynamic equilibrium [65].
Dysregulation of FGFRs
Subversion of FGFR kinase regulation and receptor hyperactivity is achieved in various ways, from overexpres-
sion of FGFRs and/or FGF ligands, to point mutations and gene fusion events [66]. Components of the FGF
signalling pathways are the most frequently mutated kinases carrying non-synonymous somatic mutations in
human cancers [67]. Though found in all FGFRs, point mutations occur most commonly in FGFR3 and are
located in all three receptor domains (Figure 4). Consequently, here we focus on FGFR3 aberrations, though in
many instances corresponding mutations can be found in FGFRs 1, 2 and 4 also. One can envisage that point
mutations cause ligand-independent activity through either stabilisation of active conformational states or
destabilisation of autoinhibitory states.
Point mutations in the extracellular domain of FGFR3, such as R248C/S249C (D2-D3 linker, thanatophoric
dysplasia and keratosis [68,69]) and C228R (D2 domain, carcinoma [67,70]) are thought to recapitulate stimu-
lation of the receptor in a ligand-independent manner through obligate receptor dimerisation. This is thought
to be achieved by disulﬁde cross-linking of the extracellular domain and/or by induction of appropriate extra-
cellular domain conformational arrangements for activation of the intracellular kinase domain. To this end,
extracellular domain mutations are localised to regions where inter-receptor cross-linking may mimic ligand-
bound states (Figure 4). Likewise, mutations in the transmembrane domain are believed to stabilise the active
(or destabilise the basal) dimerisation interfaces of the helices, shifting the equilibrium towards a ligand-
stimulated dimer arrangement. Indeed, cysteine-introducing point mutations such as G375C/G370C
(N-terminal end of the transmembrane domain, achondroplasia and keratosis [69,71]) may act to cross-link the
dimer at the extracellular domain/transmembrane domain interface and cause separation of the C-terminal
ends of the transmembrane helices. Alternatively, substitutions of large, polar residues such as G380R (achon-
droplasia and hypochondroplasia [72,73]) and A391E (Crouzon syndrome with acanthosis nigricans [74]) in
and around the transmembrane dimer interface may destabilise the basal dimerisation state by steric and
Coulombic repulsion, or potentially stabilise the active state through hydrogen-bonding [32]. Supportively,
energetic dimer stabilisation is observed following A391E substitution in the transmembrane domain [70].
The kinase domain is abundant in point mutations which are typically localised to regulatory elements such
as the molecular brake, the A-loop, the kinase hinge, the DFG-latch and others. Recently, an extensive study on
the prevalence and activating effect of point mutations in FGFR3 identiﬁed N540 (molecular brake) and K650
(A-loop) as mutational hotspots in FGFRs; these also elicit signiﬁcant stimulation of FGFR3 kinase domain
autophosphorylation [75]. Both mutation sites have been extensively characterised; molecular brake mutations
are thought to overcome autoinhibitory mechanisms and facilitate transition to the active kinase state [40],
while K650E substitution mimics A-loop Y648 (FGFR3) phosphorylation and stabilises the active, extended
A-loop conformation [41]. Surprisingly, the study showed that clinical prevalence does not directly correlate
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with stimulatory effect. For example, R669G, the most activating mutation with respect to FGFR3 kinase
domain autophosphorylation, is not a mutation hotspot, whereas G697C (of oral squamous cell carcinomas
[76]), an identiﬁed FGFR3 mutation hotspot, has no stimulatory effect on kinase activity over wild-type kinase
domain under the analysed conditions [75]. R669, due to its location at the C-terminal end of αEF in the
C-lobe likely inﬂuences kinase activity by effect on the kinase A-loop (Figure 4); in fact, crystallographic evi-
dence suggests that the corresponding residue R675 in FGFR1 contacts residues of the activation loop, stabilis-
ing the inactive kinase state. Upon R675 mutation of FGFR1, these contacts are lost and the kinase A-loop
instead occupies an ‘open’ active conformation [75]. On the other hand, G697 is located within the αF-αG
loop at the base of the C-lobe and does not appear to have any direct interactions with kinase regulatory ele-
ments (Figure 4). While the general frequency of G697C substitution in FGFR3 is disputed [77], the lack of
stimulatory action by cancer-associated mutations is not unique to G697C; in truth, there are multiple muta-
tions which are neutral-to-destabilising with respect to kinase activity, do not increase kinase domain autopho-
sphorylation nor substrate phosphorylation, yet are nonetheless observed in tumours [75]. Furthermore,
numerous deleterious point mutations in the FGFR kinase domain have been identiﬁed [75,78]. The role of
deleterious, inhibitory and neutral mutations of FGFRs in pathologies is unclear but may be dependent on cel-
lular context, and their purpose may become clearer when evaluated macroscopically with interaction partners
and signalling networks in the cell [3]. For example, the destabilising and inactivating point mutations E466K
and I538F of FGFR3, like kinase-activating N540K, enhance kinase domain binding to heat shock protein 90
(Hsp90) co-chaperone Cdc37 [79]. As Hsp90 has been implicated in the regulation and activation mechanisms
of kinases [80], altered association with cellular chaperones is consistent with the notion that dysregulation of
FGFRs by such mutations may play out at the level of the wider interactome of the kinase.
Although of relatively low clinical incidence, oncogenic gene fusions of FGFRs have recently come to light in
a variety of cancer types [81,82]. Typically, these fuse self-associating elements of a second protein in frame
with the C-terminal end (and less frequently the N-terminal end) of the receptor. Though supporting structural
evidence is lacking to date, FGFR gene fusions are expected to cause ligand-independent constitutive kinase
activity through fusion protein-induced dimerisation of the receptors, similar to that observed for the
Figure 4. Point mutations of FGFR3.
The locations of a selection of developmental disease and cancer-associated point mutations of FGFR3 in the extracellular
domain (left) (PDB: 1FQ9), the transmembrane domain (middle) (PDB: 2LZL), and the kinase domain (right) (PDB: 4K33), as
discussed in the text. As no FGFR3 ligand-dimerised extracellular domain structure is available, the extracellular domain of
FGFR1 in complex with FGF2 is shown, illustrating the localisation of FGFR3 point mutations to regions which could generate
similar dimer structures in a ligand-independent manner. Similarly, in the kinase domain, the αC helix (salmon), the αEF helix
(cyan), the hinge region (magenta), and the A-loop (yellow) are highlighted to illustrate the localisation of many point mutations
to important regulatory elements of the kinase domain.
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TPR-MET kinase fusion [83]. C-terminal fusions also lack exon 19 of the receptor, resulting in the inability to
activate PLCγ signalling through loss of its phospho-Tyr binding-site [84]. While a variety of fusion partner
genes have been identiﬁed for FGFR2 [66], gene fusions of FGFR3 almost exclusively occur with transforming
acidic coiled-coil-containing protein 3 (TACC3) [66,84]. These fusions and the FGFR3-BAIAP2L1 (brain-
Figure 5. Binding modes of FGFR inhibitors.
Crystal structures of inhibitor-bound FGFR1 and FGFR4 kinase domains, illustrating the binding modes of reversible and
irreversible (covalent) inhibitors. Reversible inhibitors can be classiﬁed into type I and type II inhibitors, differing in their binding
modes (top). Type I inhibitors such as AZD4547 bind to active, DFG in-state kinases, whereas type II inhibitors such as
ponatinib bind to inactive, DFG out-state kinases. In each instance, FGFR1 kinase domains are shown in full in cartoon
representation with transparent surfaces (light grey) and inhibitors in stick representation (purple). Additionally, the inhibitor-
binding site is expanded for each with FGFR1 (light grey) in cartoon representation alone, and F642 of the DFG motif (red) and
the gatekeeper residue V550 (orange) shown in stick representation with transparent surfaces. In the ponatinib-bound structure,
the asterisk (*) indicates the location of the ethynyl group attributed to the ability of ponatinib to accommodate gatekeeper
residue mutations and to the multikinase selectivity proﬁle of the inhibitor. The binding modes of three irreversible, covalent
inhibitors to FGFR4 and FGFR4 surrogate kinase domain (FGFR1–Y563C) are presented in expanded panels in a similar
manner (bottom). In these, where resolved in the crystal structures, the gatekeeper residue and Phe of the DFG motif is shown
as above, and the Cys residues utilised in ligand conjugation are highlighted also (yellow). In the FIIN-2-bound structure, F631
(DFG motif, FGFR4) is observed in both the DFG in- and DFG out-states, marked with a double asterisk (**). The structures
presented are: FGFR1 kinase domain bound to AZD4547 (PDB: 4V05) and ponatinib (PDB: 4V01); FGFR4 kinase domain
bound to BLU-9931 (PDB: 4XCU) and FIIN-2 (PDB: 4QQC) and of FGFR4 surrogate kinase domain (FGFR1 harbouring a
Y563C substitution) bound to H3B-6527 (PDB: 5VND).
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Table 1 Inhibitors of FGFR Part 1 of 2
Inhibitor
name Company
Measured IC50
(nM, in vitro) Progress in clinical trials (with identifiers) Ref.
Multi-kinase inhibitors
Ponatinib
(AP24534)
ARIAD
Pharmaceuticals
FGFR1: 2.2
FGFR2: 1.6
FGFR3: 18.2
FGFR4: 7.7
Phase II
NCT02272998 NCT02265341
[91]
Dovitinib
(CHIR258,
TKI258)
Novartis FGFR1: 8
FGFR3: 9
Phase II
NCT01732107†
NCT01676714
NCT01379534
NCT01576380
NCT00790426
NCT01719549
NCT01058434
NCT01831726
NCT00958971
[92]
Lucitanib
(E-3810)
Clovis Oncology FGFR1: 17.5
FGFR2: 82.5
FGFR3: 237.5
FGFR4: >1000
Phase I
NCT03117101
Phase I/II
NCT01283945
Phase II
NCT02202746 NCT02109016 NCT02053636
[93]
Nintedanib
(BIBF 1120)
Boehringer
Ingelheim
FGFR1: 69
FGFR2: 37
FGFR3: 108
FGFR4: 610
Phase II
NCT01948141
[94]
ARQ 087
(Derazantinib)
ArQule FGFR1: 4.5
FGFR2: 1.8
FGFR3: 4.5
FGFR4: 34
Phase I/II
NCT01752920
Phase II
NCT03230318
[95]
FGFR-selective inhibitors
AZD4547 AstraZeneca FGFR1: 0.2
FGFR2: 2.5
FGFR3: 1.8
FGFR4: 165
Phase I
NCT01213160
Phase I/II
NCT01824901‡
NCT02824133§
Phase II/III
NCT02965378‡
NCT00979134
NCT01202591‡ NCT01791985‡
[96]
LYS2874455 Eli Lilly FGFR1: 2.8
FGFR2: 2.6
FGFR3: 6.4
FGFR4: 6
Phase I
NCT01212107 NCT03125239‡
[97]
(NVP-)BGJ398
(Infigratinib)
Novartis FGFR1: 0.9
FGFR2: 1.4
FGFR3: 1
FGFR3K650E: 4.9
FGFR4: 60
Phase I
NCT01697605
Phase II
NCT02706691
NCT03510455
NCT01004224
NCT02150967
NCT01928459‡
NCT01975701
[98]
Debio-1347
(CH5183284)
Debiopharm
International
FGFR1: 9.3
FGFR2: 7.6
FGFR3: 22
FGFR4: 290
Phase I
NCT01948297
Phase I/II
NCT03344536‡
[99]
Erdafitinib
(JNJ-
42756493)
Janssen FGFR1: 1.2
FGFR2: 2.5
FGFR3: 3.0
FGFR4: 5.7
Phase I
NCT02421185
NCT03238196‡
Phase I/II
NCT03473743‡
Phase II
NCT03210714
NCT02952573‡
Phase III
NCT03390504‡
NCT01962532
NCT02699606
NCT01703481
NCT02365597
[100]
Continued
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speciﬁc angiogenesis inhibitor 1-associated protein 2-like protein 1) fusion are exquisitely sensitive to
FGFR-selective inhibitors in urothelial cells, indicating that these aberrations are highly targetable [82,84].
Progress towards therapies for FGFR-driven diseases
The ﬁnding that aberrant FGFR signalling has driving roles in a plethora of cancers has spurred research inter-
ests in the development of anti-FGFR treatments, predominantly taking the form of small molecule kinase inhi-
bitors (Figure 5). FGFR-targeting treatments under clinical development have been extensively reviewed
previously [85–87] and will only be summarised here.
Small molecule inhibitors of FGFRs can be classiﬁed into non-selective multi-kinase inhibitors and selective
FGFR inhibitors. The ﬁrst efforts to treat FGFR aberrations have made use of non-selective multi-kinase inhibi-
tors such as dovitinib, ponatinib and lucitanib which show pan-FGFR inhibition with nanomolar IC50 values
against FGFR family members (Table 1). With the notable exception of ponatinib, these compounds are type I
inhibitors which bind to the active, DFG-in state of FGFR kinases in an ATP-competitive manner. Often, vas-
cular endothelial growth factor receptors (VEGFRs) and platelet-derived growth factor receptors (PDGFRs) are
also targeted by these non-selective FGFR inhibitors. While the ability to target multiple kinases with a single
compound may be clinically beneﬁcial under certain circumstances, non-selective multi-kinase FGFR inhibitors
typically exhibit lower afﬁnity binding to FGFRs than other targets. Consequently, the use of these non-selective
inhibitors as FGFR-targeted therapies is associated with off-target-related toxicities [86]. The broad speciﬁcity
of many kinase inhibitors has been attributed to the high degree of structural conservation between kinases
rendering the development of selective inhibitors challenging, particularly against those in the active state. A
second subclass of reversible kinase inhibitors, type II inhibitors, bind to kinases in a DFG-out, inactive state.
To generate this kinase state, the Phe residue of the DFG-motif ‘ﬂips’ outwards, breaking the regulatory spine
and providing access to an additional hydrophobic pocket from the ATP binding-site (Figure 5) [63]. Type II
inhibitors have proved to be generally more selective than their type I counterparts, while also exhibiting
Table 1 Inhibitors of FGFR Part 2 of 2
Inhibitor
name Company
Measured IC50
(nM, in vitro) Progress in clinical trials (with identifiers) Ref.
INCB054828 Incyte Corporation FGFR1: 3–50* Phase I
NCT03235570
Phase I/II
NCT02393248‡
Phase II
NCT03011372 NCT02872714 NCT02924376
[101]
Rogaratinib
(BAY1163877)
Bayer FGFR1: 12–15
FGFR2: <1
FGFR3: 19
FGFR4: 33
Phase I
NCT01976741
Phase I/II
NCT03473756‡
Phase II/III
NCT03410693
[102]
(NVP)FGF401 Novartis FGFR4: 1.1 Phase I/II
NCT02325739‡
[103]
PD173074 Pfizer FGFR1: 22–25
FGFR3: 29
N/A [104,105]
PD166866 Pfizer FGFR1: 52.4 N/A [106]
SSR128129E N/A FGFR1: 1900 N/A [107]
A selection of small molecule multi-kinase and FGFR-selective reversible inhibitors, their measured in vitro IC50 values and clinical trial status.
Key: ‘Ref.’, reference.
*IC50 value measured using in cell assays.
†Trial terminated due to funding.
‡Drug combination study.
§Trial suspended.
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considerably slower dissociation kinetics [88,89]; however, the ability for a type II inhibitor to bind to its target
is dependent on the propensity of the kinase to ‘visit’ the DFG-out state through conformational sampling,
implying that some kinase classes may be innately more amenable to type II inhibition than others.
Furthermore, a survey of many kinase inhibitors has established that not all type II inhibitors are necessarily
more selective [90]. This is the case for the multi-kinase type II inhibitor ponatinib which was originally devel-
oped to target BCR-ABL aberrations harbouring the T315I ‘gatekeeper’ mutation in the ATP binding-site, con-
ferring resistance to earlier generation BCR-ABL inhibitors [91]. While ponatinib is able to accommodate the
Thr to Ile mutation of the gatekeeper residue in BCR-ABL through productive interactions with the unsaturated
ethynyl bond of the inhibitor, this feature is also likely to be responsible for the relatively poor kinase selectivity
of the inhibitor, which additionally exhibits potent pan-FGFR inhibition [91].
To address the toxicity issues of multi-kinase inhibitors, efforts have been made to develop FGFR-selective
kinase inhibitors, yielding numerous reversible type I inhibitor compounds with FGFR1–3 and pan-FGFR
activities (Table 1). Of these, AZD4547, a potent inhibitor of FGFRs 1–3, has shown promising responses in
preclinical and phase I clinical trials, particularly towards tumours with FGFR ampliﬁcations [108–110]. Several
phase II clinical trials evaluating the efﬁcacy of AZD4547 alone or in combination with other compounds are
active or have completed. However, preclinical studies have also indicated that resistance can be conferred to
AZD4547 via the gatekeeper mutation V555M in FGFR3 [111], much like that in BCR-ABL, highlighting the
need for continued inhibitor development and the personalisation of FGFR-targeted therapies in the clinic.
Towards this end, a second-generation FGFR-selective inhibitor Debio-1347 has been developed which has a
Table 2 Irreversible, covalent FGFR-selective inhibitors under development
Inhibitor name Company
Measured IC50
(nM, in vitro)
Progress in clinical trials
(with identifiers) Ref.
PRN1371 Principia Biopharma FGFR1: 0.6
FGFR2: 1.3
FGFR3: 4.1
FGFR4: 19.3
Phase I
NCT02608125
[112]
TAS-120 Taiho Oncology FGFR1: 3.9
FGFR2: 1.3
FGFR3: 1.6
FGFR4: 8.3
Phase I/II
NCT02052778
[117]
BLU-554 Blueprint Medicines Corporation FGFR1: 624
FGFR2: 1202
FGFR3: 2203
FGFR4: 5
Phase I
NCT02508467
[118,119]
BLU-9931 Blueprint Medicines Corporation FGFR1: 591
FGFR2: 493
FGFR3: 150
FGFR4: 3
N/A [115]
FIIN-2 N/A FGFR1: 3.09
FGFR2: 4.3
FGFR3: 27
FGFR4: 45.3
N/A [116]
FIIN-3 N/A FGFR1: 13.1
FGFR2: 21
FGFR3: 31.4
FGFR4: 35.3
N/A [116]
H3B-6527 H3 Biomedicine,
Eisai Incorporation
FGFR1: 320
FGFR2: 1290
FGFR3: 1060
FGFR4: <1.2
Phase I
NCT02834780
[114]
FGFR-selective inhibitors that have an irreversible, covalent mode of action, their measured in vitro IC50 values and their clinical
trial status. Key: ‘Ref.’, references.
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different chemical scaffold to AZD4547, PD173074 and BGJ398, and has shown inhibition efﬁcacy against Ba/
F3 cells harbouring a FGFR2 fusion with V564F gatekeeper mutation [99]. Despite efforts, no FGFR-selective
type II inhibitors in the vein of ponatinib have yet been reported, though several irreversible, covalent inhibitors
of FGFRs have been developed. Unlike reversible inhibitors, covalent inhibition confers the advantage of par-
tially circumventing high in vivo ATP concentrations [112]. Furthermore, covalent inhibition has facilitated the
development of isoform-selective inhibitors; many these covalent inhibitors are highly selective for FGFR4
(Table 2). This FGFR isoform selectivity has been achieved in at least three cases (H3B-6527, BLU-9931 and
BLU-554) through the use of the FGFR4-unique C552 residue of the hinge region which is occupied by a Tyr
residue in the corresponding position in FGFRs 1–3 (Figure 5) [113–115]. Conversely, pan-FGFR covalent
inhibition has been achieved through use of the FGFR-conserved C477 residue (FGFR4) in the cases of inhibi-
tors FIIN-2 and FIIN-3 (Table 2), both of which also exhibit activities against FGFR2 harbouring gatekeeper
mutations in cell-based assays [116]. Intriguingly, a crystal structure of FIIN-2 bound to FGFR4 indicates that
the inhibitor can bind to both DFG-in and DFG-out states of the kinase, though the inhibitor does not occupy
the additional hydrophobic pocket which is accessible in the DFG-out state (Figure 5). The signiﬁcance, if any,
of being able to bind to both states is unclear; however, FIIN-2 could form the foundation for development of
next-generation type II-like covalent inhibitors. At the time of writing, four covalent FGFR inhibitors
(PRN1371, TAS-120, H3B-6527 and BLU-554) are recruiting for phase I clinical trials.
FGFR-targeted therapies are not limited to the tyrosine kinase domain only; there have been multiple efforts to
target the extracellular domains of FGFRs also, offering further opportunities for isoform-selective inhibition
(Table 3). This is best exempliﬁed by the development of anti-FGFR2 and anti-FGFR3 monoclonal antibodies/
antibody-drug conjugates [120–124]. FP-1039, an FGF-ligand trap composed of an FGFR1 extracellular
domain-IgG1 fusion which is able to inhibit tumour growth in xenograft models, has also been developed [125].
Furthermore, a novel small molecule inhibitor (SSR128129E) which binds to FGFR extracellular domains in a
non-FGF competitive manner but induces selective, allosteric inhibition of receptor internalisation and ERK1/2
signalling has been described [107,126]. Lastly, there has also been exploration of the use of antisense therapy for
targeting FGFR4 in obesity patients (Table 3) [127].
While improved selectivity of therapies may be beneﬁcial to target speciﬁc FGFR aberrations, it is important
to recognise that clinical efﬁcacy and selectivity are not necessarily related. Highly selective FGFR-targeted
Table 3 Alternative therapies for FGFR aberrations under development
Molecule name Company Target
Progress in clinical trials
(with identifiers) Ref.
FGF ligand traps
FP-1039
(GSK3052230)
Five Prime Therapeutics FGF2 and others Phase II
NCT01244438*
[125]
Anti-FGFR monoclonal antibodies
Bemarituzumab
(FPA144)
Five Prime Therapeutics FGFR2b Phase I
NCT02318329 NCT03343301†
[120]
BAY1179470 Bayer FGFR2 Phase I
NCT01881217
[122]
LY3076226 Eli Lilly FGFR3 Phase I
NCT02529553
[123]
MFGR1877S Genentech FGFR3 Phase I
NCT01122875 NCT01363024
[124]
Antisense therapy
ISIS-FGFR4RX ISIS Pharmaceuticals FGFR4 Phase II
NCT02476019
[127]
Additional non-kinase-domain inhibitor-based therapies under development, their targets and their clinical trial status.
Key: ‘Ref.’, references.
*Trial withdrawn.
†Drug combination study.
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therapies may also be more prone to resistance development if not used in combination strategies. For example,
in addition to the gain of gatekeeper mutations detailed above, resistance to FGFR inhibitors has also been
acquired in cell lines harbouring FGFR3 ampliﬁcation by switching to ErbB family signalling [128]. Moreover,
while one aim of FGFR-selective inhibitor development is to overcome off-target effects of multi-kinase inhibi-
tors, FGFR-selective therapies are not immune to side effects, exempliﬁed by toxicity proﬁles associated with
FGFR-selective inhibitors in the clinic [86]. FGFRs are still a relatively novel target and many anti-FGFR pro-
grammes are still in their early stages; however, with multiple clinical trials active or recruiting, in many cases
with participants with speciﬁc FGFR aberrations, we should soon glean further insights that help to improve
our approaches to treatment of FGFR dysregulation.
Conclusions and perspectives
Since their ﬁrst description, it has been established that FGFRs play crucial roles in a host of physiological pro-
cesses which when dysregulated result in a plethora of pathologies. From an extensive range of studies covering
FGFR expression, structure and function, among others, mechanisms of FGFR regulation and activation have
come to light, and good progress has been made in the development of anti-FGFR therapies. Despite this, due
to the complexity of FGFR signalling inputs, outputs and FGFR interactomes, and difﬁculties faced with the
biochemical and biophysical characterisation of full-length receptors, we are still far from an integrated under-
standing of FGFR biology. Crucially, mechanisms of activation in the context of the full-length receptor are
unclear and will remain unresolved until structures of full-length FGFRs in autoinhibited, ligand-activated and
pathogenically activated modes are solved. In fact, to date there are no high-resolution full-length structures of
any receptor tyrosine kinase, severely limiting our understanding of this highly important class of kinases.
Equally, while it is recognised that activation of FGFRs can lead to differential activation of intracellular signal-
ling cascades, the underlying molecular basis of how this occurs and of how cellular context inﬂuences pheno-
typic outcome remain poorly understood. We anticipate that advances will be made in addressing these and
other remaining questions in the coming decades, and with this, new and improved strategies for treatment of
disorders arising due to aberrant FGFR signalling will develop.
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